Completed PHASE2 INTERVENTIONAL 3-arm NCT05846373

Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine

Effect of Nicotinic Acid as add-on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine: A Randomized, Double-blind, Placebo-controlled Trial

Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Conditions Migraine Prophylaxis

Interventions Nicotinic Acid 1000 MG Extended Release Oral Tablet Nicotinic Acid 500 MG Extended Release Oral Tablet Placebo

Updated 5 times since 2023 Last updated: Nov 14, 2025 Started: Nov 25, 2022 Primary completion: Jan 10, 2024 Completion: Jan 10, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Migraine Prophylaxis and is currently completed. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE2

Status: Recruiting → Completed
Sep 2024 — Dec 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Jun 2023 — Feb 2024 [monthly]

Recruiting PHASE2

First recorded

Nov 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Data source: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dhaka, Bangladesh